CVS Health Corporation (CVS)
NYSE: CVS · Real-Time Price · USD
67.43
+0.83 (1.25%)
Jul 3, 2025, 1:00 PM - Market closed
CVS Health Stock Forecast
Stock Price Forecast
The 15 analysts that cover CVS Health stock have a consensus rating of "Buy" and an average price target of $75.27, which forecasts a 11.63% increase in the stock price over the next year. The lowest target is $62 and the highest is $84.
Price Target: $75.27 (+11.63%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CVS Health stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 5 | 3 | 4 |
| Buy | 7 | 8 | 8 | 8 | 8 | 8 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 16 | 14 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Maintains $74 → $80 | Strong Buy | Maintains | $74 → $80 | +18.64% | Jun 30, 2025 |
| Barclays | Barclays | Buy Maintains $82 → $79 | Buy | Maintains | $82 → $79 | +17.16% | Jun 2, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $82 → $84 | Strong Buy | Maintains | $82 → $84 | +24.57% | May 12, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $76 → $84 | Buy | Maintains | $76 → $84 | +24.57% | May 6, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $74 → $81 | Buy | Maintains | $74 → $81 | +20.12% | May 5, 2025 |
Financial Forecast
Revenue This Year
391.12B
from 370.66B
Increased by 5.52%
Revenue Next Year
406.89B
from 391.12B
Increased by 4.03%
EPS This Year
6.19
from 3.66
Increased by 69.26%
EPS Next Year
7.10
from 6.19
Increased by 14.62%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 422.6B | 444.7B | 481.5B | ||
| Avg | 391.1B | 406.9B | 431.1B | ||
| Low | 374.0B | 380.8B | 385.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 14.0% | 13.7% | 18.3% | ||
| Avg | 5.5% | 4.0% | 6.0% | ||
| Low | 0.9% | -2.6% | -5.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.83 | 8.17 | 9.45 | ||
| Avg | 6.19 | 7.10 | 8.06 | ||
| Low | 5.89 | 5.98 | 6.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 86.5% | 31.9% | 33.1% | ||
| Avg | 69.3% | 14.6% | 13.5% | ||
| Low | 60.9% | -3.5% | -10.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.